We analyzed molecular data on 2,579 tumors from The Cancer Genome Atlas (TCGA) of
four gynecological types plus breast. Our aims were to identify shared and unique molecular …

We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising
33 diverse cancer types by utilizing data compiled by TCGA. Across cancer types, we …

We describe the landscape of genomic alterations in cutaneous melanomas through DNA,
RNA, and protein-based analysis of 333 primary and/or metastatic melanomas from 331 …

For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic
annotation data along with multi-platform molecular profiles of more than 11,000 human tumors …

Genetic alterations in signaling pathways that control cell-cycle progression, apoptosis, and
cell growth are common hallmarks of cancer, but the extent, mechanisms, and co-…

Identifying molecular cancer drivers is critical for precision oncology. Multiple advanced
algorithms to identify drivers now exist, but systematic attempts to combine and optimize them on …

We conducted comprehensive integrative molecular analyses of the complete set of tumors
in The Cancer Genome Atlas (TCGA), consisting of approximately 10,000 specimens and …

Cancer progression involves the gradual loss of a differentiated phenotype and acquisition
of progenitor and stem-cell-like features. Here, we provide novel stemness indices for …

We performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic
ductal adenocarcinoma (PDAC) specimens, including samples with characteristic low …

DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic
response. We systematically analyzed somatic alterations to provide a comprehensive view of …